DEXONE 1.5

Post-LOE

dexamethasone

Sanofi

ANDAORALTABLET

Approved

Dec 1975

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DEXONE 1.5 (dexamethasone) by Sanofi is clinical pharmacology section glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, polymyositis, systemic lupus erythematosus and 8 more indications. First approved in 1975.

Drug data last refreshed 3h ago

Mechanism of Action

CLINICAL PHARMACOLOGY SECTION Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Glucocorticoids cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Naturally…

Indications (11)

dermatomyositis polymyositis

Worked on DEXONE 1.5 at Sanofi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT07175415Phase 1/2Not Yet Recruiting

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Started Oct 2026

42 enrolled

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more

NCT07285239Phase 3Not Yet Recruiting

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Started Jul 2026

500 enrolled

Multiple Myeloma

NCT07479979Phase 1/2Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Started Jul 2026

62 enrolled

Relapse Multiple MyelomaRefractory Multiple Myeloma

NCT07559799N/ANot Yet Recruiting

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

Started May 2026

50 enrolled

Multiple Myeloma

NCT07555938Phase 3Not Yet Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Started May 2026

380 enrolled

Multiple Myeloma